TR200102784T2 - Diyabet tedavisi için ilaç - Google Patents

Diyabet tedavisi için ilaç

Info

Publication number
TR200102784T2
TR200102784T2 TR2001/02784T TR200102784T TR200102784T2 TR 200102784 T2 TR200102784 T2 TR 200102784T2 TR 2001/02784 T TR2001/02784 T TR 2001/02784T TR 200102784 T TR200102784 T TR 200102784T TR 200102784 T2 TR200102784 T2 TR 200102784T2
Authority
TR
Turkey
Prior art keywords
enzyme mixtures
pancreatin
diabetes
digestive enzyme
treatment
Prior art date
Application number
TR2001/02784T
Other languages
English (en)
Inventor
Sander-Struckmeier Suntje
Rudolf Steinborn Claus
A. Rudmann Martin
Schwanitz Diethard
Henniges Friederike
Original Assignee
Solvay Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals Gmbh filed Critical Solvay Pharmaceuticals Gmbh
Publication of TR200102784T2 publication Critical patent/TR200102784T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Mevcut bulus lipolitik, proteolitik ve amilolitik aktiviteye sahip, mikrobiyal ya da hayvan kaynakli fizyolojik olarak kabul edilebilir enzim karisimlarinin kullanimi, ama özellikle pankreatin ya da pankreatin ihtiva eden sindirim enzim karisimlari gibi sindirim enzim karisimlarinin diyabet tedavisi için kullanimi ile ilgilidir. Mevcut bulus ayrica bu tedaviye uygun ilaçlarin üretimi ile ilgilidir. Bulusun bir teskil tarzi sözkonusu lipolitik, proteolitik ve amilolitik aktiviteye sahip enzim karisiminin, özellikle pankreatin gibi sindirim enzim karisimlarinin veya pankreatin ihtiva eden sindirim enzim karisimlarinin Tip I ve Tip II diyabetin yardimci tedavilerinde kullanimi ile ilgilidir.
TR2001/02784T 1999-03-17 2000-03-15 Diyabet tedavisi için ilaç TR200102784T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19911778 1999-03-17

Publications (1)

Publication Number Publication Date
TR200102784T2 true TR200102784T2 (tr) 2002-04-22

Family

ID=7901217

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02784T TR200102784T2 (tr) 1999-03-17 2000-03-15 Diyabet tedavisi için ilaç

Country Status (23)

Country Link
US (1) US7122357B2 (tr)
EP (1) EP1162995B1 (tr)
JP (1) JP4938174B2 (tr)
CN (1) CN1221284C (tr)
AT (1) ATE242003T1 (tr)
AU (1) AU773930B2 (tr)
BR (1) BR0009012A (tr)
CA (1) CA2367355C (tr)
CZ (1) CZ20013345A3 (tr)
DE (2) DE10012095A1 (tr)
DK (1) DK1162995T3 (tr)
ES (1) ES2194720T3 (tr)
HK (1) HK1044477B (tr)
HU (1) HUP0200556A3 (tr)
NO (1) NO20014507D0 (tr)
NZ (1) NZ514826A (tr)
PL (1) PL199180B1 (tr)
PT (1) PT1162995E (tr)
RU (1) RU2268065C2 (tr)
SK (1) SK284677B6 (tr)
TR (1) TR200102784T2 (tr)
WO (1) WO2000054799A2 (tr)
ZA (1) ZA200107110B (tr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1162995B1 (de) * 1999-03-17 2003-06-04 Solvay Pharmaceuticals GmbH Enzyme zur behandlung von diabetes mellitus typ i
US7020384B1 (en) 1999-08-12 2006-03-28 Lg Electronics Inc. Method for creating and recording transport time information for data recorded on a disk
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
US7519274B2 (en) 2003-12-08 2009-04-14 Divx, Inc. File format for multiple track digital data
ES2314646T3 (es) 2004-03-22 2009-03-16 Solvay Pharmaceuticals Gmbh Composiciones farmaceuticas por via de productos que contienen lipasa , en particular de pancreatina, que contienen tensioactivos.
CA2586222A1 (en) * 2004-05-24 2005-12-08 Novozymes A/S Enzymes for pharmaceutical use
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20090047266A1 (en) * 2005-06-24 2009-02-19 Novozymes A/S Lipases for Pharmaceutical Use
AU2006261443A1 (en) * 2005-06-24 2006-12-28 Novozymes A/S Proteases for pharmaceutical use
EP1896057A2 (en) * 2005-06-24 2008-03-12 Novozymes A/S Amylases for pharmaceutical use
HUE031042T2 (en) * 2005-07-29 2017-06-28 Abbott Laboratories Gmbh Methods for producing pancreatin powder with low viral content
JP5284092B2 (ja) * 2005-08-15 2013-09-11 アボット ラボラトリーズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 腸溶コーティングに適したパンクレアチンマイクロペレットコア
EP1931316B2 (en) 2005-08-15 2017-02-22 Abbott Laboratories GmbH Controlled release pharmaceutical compositions for acid labile drugs
BRPI0614411A2 (pt) * 2005-08-15 2011-03-29 Solvay Pharm Gmbh núcleos de micropéletes de pancreatina adequados para revestimento entérico
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
WO2007053619A2 (en) * 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US8273348B2 (en) 2006-12-21 2012-09-25 Novozymes A/S Lipase variants for pharmaceutical use
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
CN101889084A (zh) 2007-12-04 2010-11-17 诺维信公司 供药学应用的蛋白酶变体
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
GB2465814B (en) * 2008-06-19 2011-10-26 Tarig Sayed Mustafa Arbab Method,composition and device for the treatment of enzymes and saccharides disorders
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
ES2732453T3 (es) 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA3050530A1 (en) 2009-01-06 2010-07-15 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
JP2012514604A (ja) 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー 大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法
RU2400245C1 (ru) * 2009-04-02 2010-09-27 Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" Средство для контроля уровня гликемии и профилактики сосудистых осложнений у больных с нарушениями углеводного обмена и сахарным диабетом типа 2
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
JP2013525488A (ja) * 2010-05-03 2013-06-20 アプタリス ファーマ リミテッド 消化酵素混合物を含有するパンクレアチンを含むマイクロペレット組成物
MX362974B (es) 2011-04-21 2019-02-28 Curemark Llc Compuestos para el tratamiento de alteraciones neuropsiquiatricas.
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
WO2013155476A1 (en) * 2012-04-12 2013-10-17 Integrative Enzymatics, Inc. Composition and method for modulating inflammatory molecules with amylase
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
AU2018250823A1 (en) 2017-04-10 2019-10-17 Curemark, Llc Compositions for treating addiction
SG11202002118XA (en) * 2017-09-19 2020-04-29 Univ Meiji Method for developing organ that lacks specific functional cell
CN109142728A (zh) * 2018-09-04 2019-01-04 深圳市鸿美诊断技术有限公司 一种定量测定粪便中胰弹性蛋白酶1的试剂盒及其应用
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3803305A (en) * 1962-12-28 1974-04-09 Rolland A Lab Process for obtaining extracts from pancreas
DE2512746C3 (de) 1975-03-22 1980-04-24 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von keimarmem, faserfreiem Pankreatin
SU908352A1 (ru) * 1980-02-11 1982-02-28 Винницкий Областной Госпиталь Для Инвалидов Отечественной Войны Способ лечени гнойных ран
DE4203315A1 (de) 1991-02-14 1992-08-20 Kali Chemie Pharma Gmbh Verfahren zur gewinnung von pankreatin
US5614224A (en) * 1995-04-20 1997-03-25 Womack; Rick W. Nutritional supplement for diabetics
EP1162995B1 (de) * 1999-03-17 2003-06-04 Solvay Pharmaceuticals GmbH Enzyme zur behandlung von diabetes mellitus typ i

Also Published As

Publication number Publication date
BR0009012A (pt) 2001-12-26
JP2002539173A (ja) 2002-11-19
HUP0200556A2 (en) 2002-06-29
AU4395000A (en) 2000-10-04
PL199180B1 (pl) 2008-08-29
EP1162995B1 (de) 2003-06-04
PT1162995E (pt) 2003-08-29
ZA200107110B (en) 2002-10-30
NZ514826A (en) 2003-08-29
SK12852001A3 (sk) 2002-02-05
HK1044477B (zh) 2006-02-03
DK1162995T3 (da) 2003-06-23
NO20014507L (no) 2001-09-17
DE10012095A1 (de) 2000-09-21
CN1343126A (zh) 2002-04-03
PL350627A1 (en) 2003-01-27
CA2367355C (en) 2012-06-05
EP1162995A2 (de) 2001-12-19
DE50002450D1 (de) 2003-07-10
HK1044477A1 (en) 2002-10-25
RU2268065C2 (ru) 2006-01-20
HUP0200556A3 (en) 2006-06-28
US7122357B2 (en) 2006-10-17
SK284677B6 (sk) 2005-09-08
CZ20013345A3 (cs) 2002-01-16
WO2000054799A3 (de) 2001-04-26
ES2194720T3 (es) 2003-12-01
ATE242003T1 (de) 2003-06-15
CA2367355A1 (en) 2000-09-21
US20020061302A1 (en) 2002-05-23
JP4938174B2 (ja) 2012-05-23
WO2000054799A2 (de) 2000-09-21
CN1221284C (zh) 2005-10-05
NO20014507D0 (no) 2001-09-17
AU773930B2 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
WO2000054799A3 (de) Arzneimittel zur behandlung von diabetes
HUP0500560A2 (hu) Mikróbás enzimek új keverékei
TR200101793T2 (tr) CCR5 modülatörleri olarak azabisikloalkanlar
TR200103428T2 (tr) IMPDH enzim inhibitörleri.
TR200200938T2 (tr) CCR5 modülatörleri olarak piperidinler
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
BRPI0510817A (pt) protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença
ATE290401T1 (de) Topisch anwendbare mittel gegen nagelpilzerkrankungen
DK0759747T3 (da) Transdermal indretning til administration gennem de-epitheliseret hud
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
RU2001126526A (ru) Лекарственное средство, предназначенное для лечения диабета
KR970064594A (ko) 노화방지용 화장품 조성물
MXPA06001173A (es) Metodo analitico para la pancreatina y composiciones comparables.
ATE214610T1 (de) Neuartige pharmazeutische verwendungen von krill- enzymen
ME00578A (en) Use of gastrointestinal lipase inhibitors
NO20023464D0 (no) Sammensetning for intestinal avlevering
BR0111989A (pt) Peptìdeos, composições e processos para o tratamento de burkholderia cepacia
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
BR0014372A (pt) Derivados de 5-hidroxissapogenina com atividade antidemência
ATE264340T1 (de) Stabilisierung von gefriergetrocknetem kuchen
ATE395064T1 (de) Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
TR200002964T2 (tr) Etilendiamin disükkinik asit ihtiva eden anti-enzim bileşimleri.
BR9609801A (pt) Petídos cíclicos análogos de somatostina com atividade inibitória do desenvolvimento de hormónio
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.